Andrea S. Blevins Primeau, PhD, MBA

Andrea S. Blevins Primeau, PhD, MBA, is a freelance medical writer and editor based in central Pennsylvania. She enjoys writing about a variety of topics including oncology, cardiovascular disease, and autoimmune disorders. Previously, she conducted research investigating the role of pharmacogenetics on the efficacy of oncologic therapies.

All articles by Andrea S. Blevins Primeau, PhD, MBA

ASH 2020

Ixazomib Plus Lenalidomide and Dexamethasone for Newly Diagnosed MM

Andrea S. Blevins Primeau, PhD, MBA

December 11, 2020

A phase 3 trial showed a trend toward improved PFS with ixazomib plus lenalidomide and dexamethasone.

ASH 2020

Umbralisib Plus Ublituximab Improved PFS vs Chemoimmunotherapy in CLL

Andrea S. Blevins Primeau, PhD, MBA

December 11, 2020

The phase 3 UNITY-CLL study showed prolonged PFS with the PI3K inhibitor plus anti-CD20 therapy combination.

ASH 2020

Response Rates in Phase 1 Studies of Hematologic Malignancies Improved Over Time

Andrea S. Blevins Primeau, PhD, MBA

December 9, 2020

Response rates have improved as phase 1 studies shifted from chemotherapy to targeted agents for hematologic malignancies.

DLBCL is a rare, B-cell non-Hodgkin’s lymphoma that affects older adults.

ASH 2020

Lenalidomide Plus Rituximab: Effective for Older Patients With R/R Indolent NHL

Andrea S. Blevins Primeau, PhD, MBA

December 6, 2020

Investigators performed post hoc subgroup analyses by age in patients with relapsed/refractory indolent lymphoma from the MAGNIFY study.

Cancer treatment can affect length of hospital stay.

ASH 2020

Poor COVID-19 Outcomes Among Patients With Hematologic Malignancies: Results From ECOVIDEHE

Andrea S. Blevins Primeau, PhD, MBA

December 6, 2020

Patients with AML or MDS were significantly more likely to die from COVID-19 vs other HMs. Most treatments did not improve survival outcomes — except corticosteroids.

IL-6 blockade may have helped a patient with multiple myeloma recover from COVID-19, but larger studies are needed to prove efficacy.

ASH 2020

Convalescent Plasma Deemed Safe and Effective in Patients With COVID-19

Andrea S. Blevins Primeau, PhD, MBA

December 6, 2020

The limited data underscore “a potential role for passive immunity in this disease,” according to the presenting researcher.

ASH 2020

Convalescent Plasma for Severe COVID-19: D-Dimer Level After Transfusion May Be a Predictive Biomarker of Mortality

Andrea S. Blevins Primeau, PhD, MBA

December 6, 2020

Convalescent plasma therapy may “potentiate the increased thrombotic risk and endotheliopathy” thought to contribute to disease pathophysiology in COVID-19.